PharmaNews.eu
  • Home
  • Business
  • R&D
  • EC
  • EMA
  • Events
  • Open Calls

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer IngelheimThe Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and almost 38,900 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit www.boehringer-ingelheim.com.

Boehringer Ingelheim RSS Channel

Filters
List of articles in category Boehringer Ingelheim
Title Published Date
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC 27 September 2018
New tablet production facility in Ingelheim: Centerpiece for global launches 31 August 2018
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica announce new partnership to develop first-in-class gene therapy for cystic fibrosis 07 August 2018
Boehringer Ingelheim R&D pushes to transcend disease boundaries 27 April 2018
Inspirational patient stories reveal the challenging realities of living with devastating rare disease 28 February 2018
Boehringer Ingelheim makes many of its best molecules openly available to the scientific community via opnMe.com to unlock their full potential 21 November 2017
Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA® 15 June 2017
Boehringer Ingelheim builds Digital Lab "BI X" with focus on innovative digital solutions in healthcare 12 June 2017
New European study highlights differing priorities in physician's therapy goals when treating advanced lung cancer patients 08 November 2016
Boehringer Ingelheim and EFSD announce first recipients of diabetes research funding 17 July 2013
Eli Lilly and Company and Boehringer Ingelheim announce regulatory submission for new insulin glargine biosimilar product 09 July 2013
Boehringer Ingelheim and the EFSD call for grant applications in diabetes research 21 January 2013
Boehringer Ingelheim launches beta social game Syrum to promote science and innovation 17 September 2012
Boehringer Ingelheim and the ETH Zurich announce diabetes and obesity research collaboration 07 September 2012
Cost effectiveness and clinical efficacy of Pradaxa® (dabigatran etexilate) versus rivaroxaban analysed 24 August 2012
Boehringer Ingelheim announces changes to Board of Managing Directors 06 July 2012
Boehringer Ingelheim once again certified as a family-friendly company 13 June 2012
One million signatures needed to call upon World Health Organisation 23 May 2012
Boehringer Ingelheim expands capabilities in biopharmaceutical process science 04 March 2012
Boehringer Ingelheim launches 'Lean-to-Clinic' program for fast drug product supply 26 January 2012

Page 2 of 5

  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next
  • End
  1. You are here:  
  2. Home
  3. Boehringer Ingelheim

About

  • Home
  • Terms and Conditions
  • Contact

Advertise

Top News Channels

  • Business
  • Research
  • EMA
  • Events

Follow us

Didn't we got you connected? If not, please note the following magic buttons:

  • Facebook
  • Twitter
  • RSS 2.0
  • Atom 1.0

Newsletter

Stay updated on the latest Pharma News. Subscribe now, it's free!

Copyright © 2023 PharmaNews.eu. All Rights Reserved.